Mealey's (April 29, 2020, 12:49 PM EDT) -- WASHINGTON, D.C. — In a combined opposition brief filed to two of three current petitions for certiorari pertaining to the tangential exception to the doctrine of equivalents (DOE) in patent infringement lawsuits, Eli Lilly and Co. on April 27 told the U.S. Supreme Court that recent rulings by the Federal Circuit U.S. Court of Appeals are consistent with controlling high court precedent and do not create a split meriting review (Hospira Inc. v. Eli Lilly and Company, No. 19-1058, U.S. Sup.; Dr. Reddy’s Laboratories Ltd., et al. v. Eli Lilly and Company, No. 19-1061, U.S. Sup.; and CJ CheilJedang Corp., et al. v. International Trade Commission, et al., No. 19-1062, U.S. Sup.)....